X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
The venture loan is intended to support Immunic’s ongoing phase 2 CALVID-1 trial of its lead asset, IMU-838, in patients with moderate coronavirus disease 2019 (COVID-19).
Lead Product(s): Vidofludimus calcium anhydrous,Oseltamivir Phosphate
Therapeutic Area: Infections and Infectious Diseases Product Name: IMU-838
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: European Investment Bank
Deal Size: $28.6 million Upfront Cash: Undisclosed
Deal Type: Funding October 20, 2020
Details:
The IONIC trial is a prospective, randomized, parallel-group, open-label phase 2b study, designed to evaluate efficacy & safety of IMU-838 in combination with the neuraminidase inhibitor, Oseltamivir, in approximately 120 adult COVID-19 patients.
Lead Product(s): Vidofludimus calcium anhydrous,Oseltamivir Phosphate
Therapeutic Area: Infections and Infectious Diseases Product Name: IMU-838
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
